Louisville Metabolic and Atherosclerosis Research Center

Institution (Facility)

Homepage ROR

Also Known As

Lipid Center, Louisville Metabolic and Atherosclerosis Research Center · Acronym: L-MARC

703

Publications

84K

Citations

Authors

233

Concepts

About

Louisville Metabolic and Atherosclerosis Research Center is a facility institution in Louisville, United States known for medicine, cardiovascular disease, and atherosclerosis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	62	264	26.9K
2	Public Health	27	65	8.3K
3	Health Sciences	22	66	4.5K
4	Engineering	2	5	476
5	Natural Sciences	2	8	254

Louisville Metabolic and Atherosclerosis Research Center

703

Publications

84K

Citations

Page 1

	Year	Citations
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events Marc S. Sabatine, Robert P. Giugliano, Stephen D. Wiviott, New England Journal of Medicine Heart FailureLipid PeroxidationHyperlipidemiaPharmacotherapyOxidative Stress	2015	1.5K
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR**STELLAR = Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin. Trial) Peter H. Jones, Michael H. Davidson, Evan A. Stein, The American Journal of Cardiology Lipid DisorderCardiovascular DiseaseMedicineClinical TrialsHyperlipidemia	2003	1.4K
Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management Steven R. Smith, Neil J. Weissman, Christen M. Anderson, New England Journal of Medicine	2010	911
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2 Terry A. Jacobson, Kevin C. Maki, Carl E. Orringer, Journal of clinical lipidology	2015	778
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report Terry A. Jacobson, Matthew K. Ito, Kevin C. Maki, Journal of clinical lipidology Metabolic SyndromeLipid DisorderPatient-centered ManagementHealth PolicyCardiovascular Disease	2015	773
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients Steven E. Nissen, A. Michael Lincoff, Danielle M. Brennan, New England Journal of Medicine	2023	770
Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol Kausik K. Ray, Harold Bays, Alberico L. Catapano, New England Journal of Medicine	2019	758
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial Frederick J. Raal, Evan A. Stein, Robert Dufour, The Lancet Metabolic SyndromeLipid DisorderHeterozygous Familial HypercholesterolaemiaOxysterolMedicine	2014	734
Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial Frederick J. Raal, Narimon Honarpour, Dirk Blom, The Lancet Metabolic SyndromeLipid DisorderHomozygous Familial HypercholesterolaemiaOxysterolMedicine	2014	720
Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol Evan A. Stein, Scott Mellis, George D. Yancopoulos, New England Journal of Medicine	2012	659

Page 1